Table 3.
Selected Ongoing Adjuvant clinical trials in TNBC
| NCT number | Phase | Treatment Intervention |
|---|---|---|
| Platinum agents | ||
| NCT02445391 | III | Platinum Based Chemotherapy or Capecitabine in Treating Patients with Residual TN Basal-Like Breast Cancer Lollowing NACT |
| NCT04297267 | II | Gemcitabine Plus Cisplatin in the Treatment of Patients with Non-pCR TNBC Lollowing standard NACT |
| Immune checkpoint inhibitors | ||
| S1418/BR006 Keynote-242 NCT02954874 |
III | Pembrolizumab as Adjuvant Therapy for TNBC with residual cancer after NACT |
| IMpassion 030 NCT03498716 |
III | Atezolizumab In Combination with Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients with Operable TNBC |
| NCT02926196 | III | Adjuvant Treatment for High-risk TNBC Patients with Avelumab |
| PHOENIX DDR/Anti-PD LI trial Residual TN Basal-Like Breast Cancer Lollowing NACT | ||
| NCT04297267 | II | Gemcitabine Plus Cisplatin in the Treatment of Patients with Non-pCR TNBC Lollowing standard NACT |
| Immune checkpoint inhibitors | ||
| S1418/BR006 Keynote-242 NCT02954874 |
III | Pembrolizumab as Adjuvant Therapy for TNBC with residual cancer after NACT |
| IMpassion 030 NCT03498716 |
III | Atezolizumab In Combination with Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients with Operable TNBC |
| NCT02926196 | III | Adjuvant Treatment for High-risk TNBC Patients with Avelumab |
| PHOENIX DDR/Anti-PD LI trial NCT03740893 |
II | A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response (DDR) Inhibition and/or Anti-PD-L1 Immunotherapy in Patients with NACT Resistant Residual TNBC |
| PARP inhibitors | ||
| OlympiA NCT02032823 |
III | Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy |
| Therapeutic Vaccine | ||
| GLORIA Trial NCT03562637 |
III | Adagioxad Simolenin (OBI 822)/OBI 821 vs placebo Treatment for High Risk Early Stage TNBC Patients with Residual Invasive Disease Following NACT |